about
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesIs there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? YesComparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects.Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins.Sitagliptin: Is It Effective in Routine Clinical Practice?Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioningThe role of incretin therapy at different stages of diabetes.Recent Advances in Effect-directed Enzyme Assays based on Thin-layer Chromatography.GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation.Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes.A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin-Angiotensin-Aldosterone System Blockers.Skin fibrosis. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential.Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database.Type 2 diabetes: an expanded view of pathophysiology and therapy.Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).Putting medications where they belong: practical advice for managing type 2 diabetes in clinical practice.Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis.Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes.Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases.A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes.A role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretion.The Antidiabetic Mechanisms of Polyphenols Related to Increased Glucagon-Like Peptide-1 (GLP1) and Insulin Signaling.Hypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes.DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case-Control Study.Anti-diabetic effect of a traditional Chinese medicine formula.Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis.
P2860
Q26827955-B7B740B5-3AB9-4D63-8998-375C34B94FC9Q33610682-A39B4389-A420-4E7D-AE58-1512667F72D5Q33727891-C88FD1FE-E2C5-4ECA-97B5-DF246AC6EE8AQ34016159-E8B820F9-A810-4745-8DF3-73DC023B1EA6Q34374336-EE7DB17F-A730-42AC-B63B-E98007590AB5Q35022184-6146A6D8-5A30-4982-B241-A2DA0C1CBF38Q35671855-94AF5840-C8EB-439B-94D1-80008D5C05B0Q35693453-2DD4307B-B150-45D2-953F-4EE9A5D9918FQ35760288-42663222-25B0-464E-8C07-92CE1251D12FQ36266184-23CB6823-F545-45EC-B74E-E1FD82F77375Q36335898-63149E94-512F-4FA6-A919-8CB3AA677285Q36942072-4CE89A66-CD74-4996-9FF0-48C127263E6FQ37164446-A9B386DE-5C4D-4C9D-BDA4-3DA5DB5550A9Q37248403-F7F43E87-F69E-4E67-97B0-4C24F164F4A8Q37383098-79A7146D-16BA-488B-A856-C160AC70837FQ37677872-AA91903B-A670-4743-B54C-1A5584078037Q37750278-EC071061-DC85-4081-A5BB-0476D9A6BA65Q37835612-E3BC61E9-C571-4E8D-A836-ADB676DD789EQ37857686-F2465705-AACA-4626-A7EB-005F77637C05Q37941683-2CCA6BB8-E498-445E-9441-7D662F3A9C8FQ37948831-E83E174C-76DB-449A-A506-56BDA05903D8Q38076486-6B586B4D-7E8C-487D-9375-956BCC810259Q38077284-DECA9825-E219-44E3-888D-8443619297BFQ38129805-591C9465-30FF-4B42-B205-DFD7C7226204Q38731788-AB9D0A0B-2B13-47DB-B080-BEF20FC48FFFQ38910367-3956E6EA-5550-4C53-874E-FC96C1F1C073Q39015682-3FFB7CAF-43AF-4BC0-B221-751ACA87CFB9Q39337962-742C8613-C124-48F7-A25D-AC513DB32061Q41877149-BF77F8CD-E611-4A5B-82E6-AE51947DB225Q47318130-20E8C433-5EC1-4C40-B9F2-1DE5C4E1AC7FQ51352693-A01DF8D9-A714-4D0E-B438-5061C4C0C035Q54242863-2F998602-E526-449A-A934-6F547C0007AB
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
DPP-4 inhibitors.
@ast
DPP-4 inhibitors.
@en
DPP-4 inhibitors.
@nl
type
label
DPP-4 inhibitors.
@ast
DPP-4 inhibitors.
@en
DPP-4 inhibitors.
@nl
prefLabel
DPP-4 inhibitors.
@ast
DPP-4 inhibitors.
@en
DPP-4 inhibitors.
@nl
P1476
DPP-4 inhibitors.
@en
P2093
P304
P356
10.1016/J.BEEM.2007.07.005
P577
2007-12-01T00:00:00Z